DYN vs EXEL
Dyne Therapeutics, Inc. vs Exelixis — AI-powered side-by-side comparison
DYN
Dyne Therapeutics, Inc.
62
Buy
VS
| Metric | DYN | EXEL |
|---|
| AI Score |
62
|
67
|
| Price |
$26.70
|
$51.30
|
| P/E Ratio |
-8.02×
|
15.60×
|
| ROE |
-45.9%
|
36.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
96.5%
|
| Debt / Equity |
0.03×
|
0.09×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
71.9
|
41.0
|
| Beta |
1.084
|
0.422
|
| Expected Upside |
—
|
+8.7%
|
AI Committee View
Current Innellis committee reasoning for DYN versus EXEL.
EXEL leads by 5 points.
EXEL scores 67/100 (Buy) versus DYN at 62/100 (Buy).
DYN Committee View
60% agreement
5 analysts
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.15) -- balance sheet can absorb a shock — Risk
Bear Case
- ROE of only -64.3% -- cheap may mean cheap for a reason — Value
- RSI at 72 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical